Literature DB >> 11289466

Subclinical states of glucose intolerance and risk of death in the U.S.

S H Saydah1, C M Loria, M S Eberhardt, F L Brancati.   

Abstract

OBJECTIVE: Although clinically evident type 2 diabetes is a well-established cause of mortality, less is known about subclinical states of glucose intolerance. RESEARCH DESIGN AND METHODS: Data from the Second National Health and Nutrition Examination Survey Mortality Study, a prospective study of adults, were analyzed. This analysis focused on a nationally representative sample of 3,174 adults aged 30-75 years who underwent an oral glucose tolerance test at baseline (1976-1980) and who were followed up for death through 1992.
RESULTS: Using 1985 World Health Organization criteria, adults were classified as having previously diagnosed diabetes (n = 248), undiagnosed diabetes (n = 183), impaired glucose tolerance (IGT) (n = 480), or normal glucose tolerance (n = 2,263). For these groups, cumulative all-cause mortality through age 70 was 41, 34, 27, and 20%, respectively (P < 0.001). Compared with those with normal glucose tolerance, the multivariate adjusted RR of all-cause mortality was greatest for adults with diagnosed diabetes (RR 2.11, 95% CI 1.56-2.84), followed by those with undiagnosed diabetes (1.77, 1.13-2.75) and those with IGT (1.42, 1.08-1.87; P < 0.001). A similar pattern of risk was observed for cardiovascular disease mortality.
CONCLUSIONS: In the U.S., there was a gradient of mortality associated with abnormal glucose tolerance ranging from a 40% greater risk in adults with IGT to a 110% greater risk in adults with clinically evident diabetes. These associations were independent of established cardiovascular disease risk factors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11289466     DOI: 10.2337/diacare.24.3.447

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  36 in total

Review 1.  The metabolic syndrome in children and adolescents.

Authors:  Martha L Cruz; Michael I Goran
Journal:  Curr Diab Rep       Date:  2004-02       Impact factor: 4.810

Review 2.  Exercise training: can it improve cardiovascular health in patients with type 2 diabetes?

Authors:  K J Stewart
Journal:  Br J Sports Med       Date:  2004-06       Impact factor: 13.800

3.  Determinants of normoglycemia and contribution to cardiovascular risk factors in a Chinese population: the Hong Kong Cardiovascular Risk Factor Study.

Authors:  G Neil Thomas; S M McGhee; C M Schooling; S Y Ho; K S L Lam; E D Janus; T H Lam
Journal:  J Endocrinol Invest       Date:  2006-06       Impact factor: 4.256

4.  Regression to Normal Glucose Regulation in American Indians and Alaska Natives of a Diabetes Prevention Program.

Authors:  Katherine A Pratte; Ann Johnson; Janette Beals; Ann Bullock; Spero M Manson; Luohua Jiang
Journal:  Diabetes Care       Date:  2019-06-08       Impact factor: 19.112

Review 5.  Endothelial dysfunction in human diabetes.

Authors:  Sari Mäkimattila; Hannele Yki-Järvinen
Journal:  Curr Diab Rep       Date:  2002-02       Impact factor: 4.810

6.  Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

Authors:  Louise Profit; Paul Chrisp; Carole Nadin
Journal:  Core Evid       Date:  2008-06

7.  Could pre-diabetes be considered a clinical condition? opinions from an endocrinologist and a cardiologist.

Authors:  Maria Eliane C Magalhães; Breno A Cavalcanti; Saulo Cavalcanti
Journal:  Diabetol Metab Syndr       Date:  2010-01-15       Impact factor: 3.320

8.  Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence.

Authors:  James P Boyle; Theodore J Thompson; Edward W Gregg; Lawrence E Barker; David F Williamson
Journal:  Popul Health Metr       Date:  2010-10-22

9.  Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk?

Authors:  Ahmad Aljada; Kshitij Ashwin Shah; Shaker A Mousa
Journal:  PPAR Res       Date:  2009-08-19       Impact factor: 4.964

10.  GHb level and subsequent mortality among adults in the U.S.

Authors:  Sharon Saydah; Min Tao; Giuseppina Imperatore; Edward Gregg
Journal:  Diabetes Care       Date:  2009-04-28       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.